PubRank

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Clinical Trial ID NCT01306045

PubWeight™ 26.70‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01306045

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005 6.64
2 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008 4.82
3 Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 2015 4.38
4 CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003 2.07
5 Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011 1.25
6 The MAPK pathway across different malignancies: a new perspective. Cancer 2014 1.22
7 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
8 Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013 1.12
9 EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 2014 1.08
10 Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 2013 1.03
11 From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2012 1.00
12 Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep 2014 1.00
13 High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 2015 0.97
14 CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J Clin Invest 2014 0.95
15 New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 2012 0.93
16 Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J Pers Med 2014 0.92
17 Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 2016 0.89
18 Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med 2015 0.88
19 KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach. Transl Lung Cancer Res 2013 0.84
20 Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol 2012 0.82
21 Whole genome and transcriptome sequencing of a B3 thymoma. PLoS One 2013 0.81
22 Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr Oncol 2012 0.81
23 The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 2014 0.78
24 Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 2014 0.78
25 Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res 2016 0.77
26 Clinical potential of gene mutations in lung cancer. Clin Transl Med 2015 0.77
27 Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol 2016 0.77
28 "Pseudocavitation" in thymic carcinoma during treatment with sunitinib. J Thorac Oncol 2013 0.76
29 CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. Oncotarget 2016 0.75
Next 100